Table of Contents
A biotech patent landscape is the structured read of who is filing, where, and on what across life science — the map a strategy or IP team uses to see filing momentum, the assignees that dominate a modality, and the white space still open to a new entrant. Biotechnology sits in the fastest-moving corner of the patent system: the EPO recorded biotechnology as one of its fastest-growing fields in 2024, even as pharmaceutical filings dipped, and WIPO logged a record 3.7 million patent applications worldwide. In a field where a single platform patent can gate an entire therapeutic class, filing blind is expensive; reading the landscape first is how the spend is aimed.
What the Biotech Patent Landscape Shows in 2024
A biotech patent landscape turns a scattered mass of filings into three answers a life-science strategy team can act on: is innovation in a modality accelerating or cooling, which organisations already hold the ground, and where is the ground still open. Each is a different cut of the same public record — the filing trend, the assignee ranking, and the white-space gap — and each drives a different decision, from where to file next to who to license from or design around.
The macro backdrop makes the exercise urgent. WIPO’s World Intellectual Property Indicators 2025 put global patent applications at a record 3.7 million in 2024, up 4.9% on the year and the fastest growth since 2018, with Asia now filing roughly 70% of the world’s applications. Against that all-field surge, life science tells a two-speed story that a landscape has to separate rather than blur.
The EPO Patent Index 2024 is where that split shows. Biotechnology filings at the EPO rose 5.4% to 8,479, one of the office’s fastest-growing fields and up for a run of years, while pharmaceutical filings fell 13.2% to 8,359 — the two life-science fields moving in opposite directions in the same year. WIPO’s PCT Yearly Review 2025 echoes the pharma softness, with pharmaceuticals down 5.6% as an international-filing field. A biotech patent landscape reads that divergence at the modality level, so a team can tell a genuine platform wave from a portfolio being quietly wound down.
What makes the biotech patent landscape different from a general technology scan is the concentration of value in a few gating claims. A single foundational patent on a delivery vector, an editing system or an antibody scaffold can control access to an entire therapeutic class, so counting filings is not enough — the landscape has to weight them by how much of a modality each one commands. That distinction separates a portfolio that protects a franchise from one that merely decorates it.
Where the Filings Are: Offices and Country Concentration
Life-science innovation is filed through a small number of offices, and knowing which one leads a modality tells you where enforcement and prior art will concentrate. WIPO’s PCT Yearly Review 2025 shows international filing tilting hard toward East Asia, with the top five origins taking 77.8% of all PCT applications in 2024.
| PCT origin (2024) | Applications |
|---|---|
| China | 70,160 |
| United States | 54,087 |
| Japan | 48,397 |
| South Korea | 23,851 |
| Germany | 16,721 |
For biotech the geographic pattern is more concentrated than the totals suggest, because the science clusters where the universities, hospitals and venture capital sit. WIPO singles out the Boston–Cambridge region, where pharmaceuticals make up 21.5% of all PCT applications — a life-science density found almost nowhere else. A biotech patent landscape that ignores this geography misreads both where a competitor is protected and where a freedom-to-operate risk actually bites, because a family filed only in one region does not block a launch in another.
The two anchor offices for the field remain the EPO and the USPTO, with China’s CNIPA rising fast on volume. Reading origin against destination is what tells a strategy team whether a competitor is protecting a home market or building a genuine multi-jurisdiction wall — the difference between a design-around and a licence.
Who Owns the Biotech Patent Landscape
The assignee ranking is where a landscape stops being a chart and starts naming competitors. In the EPO Patent Index 2024, the top filers across the biotechnology and pharmaceutical fields are led by Hoffmann-La Roche, Sanofi and France’s INSERM — the integrated pharma houses and public research institutes that anchor European life-science R&D.
One quirk of the biotech patent landscape is worth stating plainly: the overall top patent filers are not pharma at all. The EPO’s single largest applicant in 2024 was Samsung, and WIPO’s PCT top ranks are filled by Huawei, Samsung and Qualcomm — electronics and telecom, not medicine. Life-science leadership is real but field-specific, which is exactly why assignee benchmarking has to be done modality by modality rather than off a global count.
Benchmarking those portfolios against each other is the point. Two companies with similar filing counts can hold completely different positions — one deep in antibodies, another in gene therapy — and it is the overlap, not the raw count, that predicts where cross-licensing pressure and litigation risk will land. That read connects directly to how a buyer prices a portfolio in IP valuation.
The Technology Clusters Driving Growth
A useful biotech patent landscape is cut into technology clusters, because ‘biotech’ is far too broad to guide a filing budget. The modalities carrying the current growth are distinct, and each has its own leaders and its own crowding:
- Gene editing (CRISPR-Cas) — the most contested ground in the field. WIPO’s 2024 review counts more than 11,000 CRISPR-related patent families, with the foundational rights split between the CVC group (UC Berkeley, University of Vienna and Emmanuelle Charpentier) and the Broad Institute — a live ownership dispute that a landscape has to map before anyone files.
- mRNA and vaccines — the modality the pandemic accelerated, now spreading beyond COVID into oncology and rare disease. WIPO’s dedicated COVID-19 vaccines and therapeutics patent landscape report is the primary map of who holds the platform claims.
- Cell & gene therapy — the fastest-commercialising modality, with the FDA now listing 59 approved cell and gene therapy products; the delivery-vector and manufacturing patents are the choke points.
- Antibodies and biologics — the revenue core of modern pharma, where scaffold and format patents gate whole franchises.
- Biosimilars — the follow-on wave riding the patent cliff, where freedom-to-operate work matters more than new filing.
The divergence in the 2024 data — biotechnology filings up while pharmaceutical filings fell — is itself a cluster signal: innovation is migrating from small-molecule chemistry toward the platform modalities above. A landscape maps each cluster’s filing curve separately so a team can back the rising modality rather than the crowded one.
White Space: Where the Landscape Is Still Open
The most valuable output of a biotech patent landscape is not the list of what exists but the map of what does not — the white space where filing density is low, incumbents are absent, and a new claim can still stake real ground. In a field where the leaders each hold foundational rights, white space is rarely a whole modality; it is a specific combination — a delivery vector for a particular tissue, an editing approach for a particular target — that the crowd has not yet reached.
Finding it means reading the landscape at the claim and classification level, not the headline count. A modality can look saturated by volume while a specific indication or formulation angle inside it sits almost unclaimed. That is the difference between a landscape that tells a client the field is ‘busy’ and one that hands them a defensible place to file, which is the same discipline behind our competitive patent landscape analysis.
White space also cuts the other way — as a warning. A gap every major assignee has deliberately avoided is often a gap for a reason: a failed target, an unpatentable natural product, or a regulatory dead end. A credible white-space readout distinguishes genuine opportunity from the field’s collective judgement that a direction is not worth pursuing.
The timing of a white-space move matters as much as its location. In fast-moving clusters such as gene editing and cell therapy, an opening that is real this year can be filled as the leaders redirect their filing budgets, so the landscape is read as a moving picture rather than a snapshot. Tracking filing velocity into and out of a modality tells a client not only where the space is, but how long the window to claim it is likely to stay open.
Reading the Landscape for Strategy, FTO and Deals
A biotech patent landscape earns its cost when it feeds a decision. For R&D leadership it sets the filing programme — which modalities to build in, which to design around, and where a defensive publication beats a patent. For freedom-to-operate it flags the foundational families a therapeutic programme has to clear before it advances, weighted by the geographies that actually matter to the launch.
For dealmakers the landscape is the backdrop to valuation. A target’s portfolio means little as a count; it means a great deal once you can see the modalities it dominates, the giants it overlaps, and the licence-in obligations that travel with the assets. That read is exactly what an M&A IP due diligence review turns into a defensible number and a red-flag register, and it feeds directly into how a sub-sector is sized in our biotech market sizing case study.
Because life-science value concentrates in a few gating patents, the landscape also tells a client where they will have to license rather than litigate — the modalities where a foundational holder sits astride the whole class and a licence is the price of entry. Reading a competitor’s filing pattern over time — which modalities it is entering, which it is quietly abandoning by letting families lapse, and where its velocity is accelerating — lets a strategy team anticipate the next battleground rather than react to it.
How to Commission a Biotech Patent Landscape
The sharper the brief, the more decision-ready the landscape. Name the modality — gene editing, mRNA, cell and gene therapy, antibodies or biosimilars — the geographies that matter to your programme, and the decision the study has to serve, whether that is a filing programme, a freedom-to-operate clearance or a diligence read on a target. The scope of the search follows the question.
From there we rebuild the biotech patent landscape from the primary record: filing and grant trends pulled by office and classification, assignees normalised so one organisation filing under several names is counted once, the field split into modalities, and the white space mapped at a level a team can actually file into. Every figure is tied back to EPO, WIPO or USPTO data so the readout survives a board or an investment committee.
The result is a biotech patent landscape a strategy team can act on the day it lands — not a static count of the past, but a map of where the field is moving, who already holds it, and where it is still open to you.
What You Receive
- A filing-trend analysis — application and grant momentum by year, office and modality, separating biotech from pharma
- Top-assignee benchmarking — who owns the field, how fast each is growing, and where portfolios overlap
- A technology-cluster map splitting the field into gene editing, mRNA and vaccines, cell & gene therapy, antibodies and biosimilars
- A white-space readout — the modalities and geographies where filing density is still low enough to claim position
- A primary-source evidence pack citing EPO, WIPO and USPTO data behind every number
Data Sources & References
This analysis draws on primary patent and market data:
- EPO Patent Index 2024 — European filing data showing biotechnology up 5.4% to 8,479 filings while pharmaceuticals fell 13.2% to 8,359, with Roche, Sanofi and INSERM among top life-science filers.
- WIPO World Intellectual Property Indicators 2025 — Patents highlights — Record 3.7M global applications in 2024 (+4.9%), with Asia filing roughly 70% of the world total.
- WIPO PCT Yearly Review 2025 — International filing data: ~273,900 PCT applications in 2024, pharmaceuticals down 5.6%, top-five origins at 77.8%, and the Boston–Cambridge pharma concentration at 21.5%.
- WIPO — CRISPR-Cas: Navigating the Patent Landscape (2024) — WIPO's review of the CRISPR patent landscape, counting more than 11,000 patent families and mapping the CVC vs Broad Institute foundational dispute.
- FDA / CBER — Approved Cellular and Gene Therapy Products — The regulator's list of 59 approved cell and gene therapy products, the demand signal behind the fastest-commercialising modality.
Request a Biotech Patent Landscape
Tell us the modality and the decision it has to serve, and we will map the filings, the owners and the white space against the primary record.
Request a Biotech Patent Landscape
Related PerspireIP work: Market Sizing & Opportunity Analysis · Biotech Market Sizing Case Study · M&A IP Due Diligence.
Frequently Asked Questions
What is a biotech patent landscape?
It is a structured analysis of life-science patent filings — filing and grant trends by office and modality, the top assignees and their overlaps, a technology-cluster map, and the white space still open. It turns the public patent record into a map a strategy, R&D or deal team can act on.
Which organisations dominate the biotech patent landscape?
In the EPO Patent Index 2024, Hoffmann-La Roche, Sanofi and INSERM lead the biotechnology and pharmaceutical fields. Notably the overall top filers are electronics firms such as Samsung and Huawei, not pharma — which is why assignee benchmarking in life science is done modality by modality rather than off a global count.
Is biotech patenting growing or shrinking?
It depends on the modality. The EPO Patent Index 2024 shows biotechnology filings up 5.4% to 8,479 while pharmaceuticals fell 13.2% to 8,359, and WIPO’s PCT review shows pharmaceuticals down 5.6%. The landscape reads that divergence as innovation migrating from small-molecule chemistry toward platform modalities like gene editing and cell therapy.
What technology clusters matter most right now?
Gene editing (CRISPR-Cas), mRNA and vaccines, cell & gene therapy, antibodies and biologics, and biosimilars. Gene editing is the most contested — WIPO counts over 11,000 CRISPR patent families — while cell and gene therapy is the fastest-commercialising, with the FDA now listing 59 approved products.
How does a landscape find white space in such a crowded field?
By reading the record at the claim and classification level rather than the headline count. A modality can look saturated by volume while a specific indication, target or delivery-vector angle inside it sits almost unclaimed — that specific combination is the white space worth filing into.
How is a biotech patent landscape used in an acquisition?
It shows which modalities a target actually dominates, which foundational holders its portfolio overlaps, and what licence-in obligations travel with the assets — the inputs an M&A IP due diligence review turns into a defensible valuation range and a red-flag register.